메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Xinhua Silk Road: 중국 기업인들, 문화유산 계승과 혁신 모색 위한 회담 개최

[ 메디채널 김갑성 기자 ] 베이징 2025년 11월2일 -- 28일(화) 열린 장주편자황제약(Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.)과 구이저우마오타이그룹(Kweichow Moutai Group) 이사회 의장 간 심도 있는 대화에서 전통 중국 문화의 계승과 혁신을 촉진하기 위한 공동 노력의 중요성이 강조됐다. 중국의 유서 깊은 브랜드 계승 방안 등 관련 주제를 논의한 후 편자황제약의 린즈후이(Lin Zhihui) 이사회 의장과 구이저우마오타이그룹의 천화(Chen Hua) 의장은 양사가 이 주제에서 모범적인 역할을 충실히 보여주기로 합의했다. 양사는 모두 중국의 유서 깊은 브랜드로 유명하며, 국가급 무형문화유산에 등재된 생산 기술을 보유하고 있다. 또한 각자의 활동 분야에서 깊은 역사와 문화적 기반을 토대로 큰 영향력을 발휘하고 있다. 명나라(1368-1644) 시기 황실의(帝国의)의 비방에서 유래한 편자황제약 제품은 현재 보호받는 전통 중국 약제로 분류된다. 린 의장은 회담에서 '본질을 계승한 혁신(essence inheritance-based inno
- 김갑성 기자
- 2025-11-02 03:36
Zhimeng Biopharma's investigational drug CB03-154 for amyotrophic lateral sclerosis has achieved the first patient first dose milestone in the phase 2/3 pivotal clinical trial.

SHANGHAI, Oct. 31, 2025 -- Shanghai Zhimeng Biopharma Inc. ( "Zhimeng") announced that its self-developed new-generation potassium channel opener CB03-154 for the treatment of amyotrophic lateral sclerosis (ALS) has officially initiated the phase 2/3 clinical trial and completed the first patient first dose at the 2nd Affiliated Hospital of Hebei Medical University. Previously (in July 2025), CB03-154 received approval from the China Center for Drug Evaluation (CDE) to conduct the ALS phase 2/3 adaptive clinical trial. The CB03-154 has also been granted orphan drug status in the Uni
- 김갑성 기자
- 2025-10-31 21:00
Bio Farma Indonesia Leads Global Vaccine Manufacturers as Host of the 26th DCVMN AGM in Bali

BALI, Indonesia, Oct. 31, 2025 -- Bali, October 29, 2025, Indonesia, through Bio Farma, is hosting the 26th Annual General Meeting (AGM) of the Developing Countries Vaccine Manufacturers Network (DCVMN) in Bali on October 29–31, 2025. The forum brings together vaccine manufacturers, global health institutions, and partners under the theme Advancing innovation and building a resilient vaccine ecosystem for a safer world. As host and founding member, Indonesia reinforces its role as a key driver of global vaccine self-reliance and health resilience. The AGM serves as a strategic
- 김갑성 기자
- 2025-10-31 20:01
Elevaris Medical Devices Names New Chief Engineering and Operations Officer

BOSTON, Oct. 31, 2025 -- Elevaris Medical Devices, a Contract Development and Manufacturing Organization for industry-leading multi-national healthcare companies, announced the appointment of its new Chief Engineering and Operations Officer, Salvador Montes. Montes will be responsible for global engineering strategy and operations across the company's facilities in the United States, the United Kingdom, and South Korea. "Sal brings vast global experience and is incredibly pedigreed in execution, operational excellence, and continuous improvement," said
- 김갑성 기자
- 2025-10-31 20:00
Alpha Fusion Initiates Company-Sponsored Clinical Trial of Alpha-Emitting Radiopharmaceutical af-001 in Patients with Differentiated Thyroid Cancer

– Aiming to establish af-001 as a new therapeutic option for radioactive iodine (RAI)-naïve patients with differentiated thyroid cancer – TOKYO, Oct. 31, 2025 -- Alpha Fusion Inc. (Headquarters: Chiyoda-ku, Tokyo; CEO: Sunao Fujioka; hereinafter "Alpha Fusion") today announced the initiation of a company-sponsored Phase I clinical trial (jRCT2031250472) of the alpha-emitting radiopharmaceutical af-001, which contains [211At]NaAt as its active pharmaceutical ingredient, in patients with differentiated thyroid cancer (papillary and follicular carcinoma). Thi
- 김갑성 기자
- 2025-10-31 20:00
엘레바리스 메디컬 디바이시스, 살바도르 몬테스 신임 엔지니어링 및 운영 책임자 임명

보스턴, 2025년 10월 31일 -- 글로벌 헬스케어 기업들을 위한 계약 개발•제조 전문기업(CDMO) 엘레바리스 메디컬 디바이시스(Elevaris Medical Devices)가 살바도르 몬테스(Salvador Montes)를 신임 엔지니어링 및 운영 책임자로 임명했다고 발표했다. 몬테스는 앞으로 미국, 영국, 한국 등 엘레바리스의 주요 생산 시설을 아우르는 글로벌 엔지니어링 전략 및 운영 관리를 총괄하게 된다. 리처드 즈레비에크(Richard Zrebiec) 엘레바리스 메디컬 디바이시스 최고경영자(CEO)는 "살바도르는 글로벌 현장에서 폭넓은 경험을 쌓았으며 실행력, 운영 우수성, 지속적 개선 역량을 모두 갖춘 인물"이라며 "그가 가져올 조직적 규율, 에너지, 비전이 우리의 엔지니어링•제조 경쟁력을 한층 강화하고, 고객에게 탁월한 가치를 제공하는 성장 동력이 될 것"이라고 말했다. 몬테스는 의료기기, 항공우주, 소비재 산업 전반에서 25년 이상 다중 거점 제조 및 공급망 운영을 이끌어온 전문가로, 린(Lean) 전환, 신규 사업, 인수합병(M&
- 김갑성 기자
- 2025-10-31 20:00
Kexing Biopharm Showcases Global Strategy and Partnership Opportunities at CPHI Frankfurt 2025

FRANKFURT, Germany, Oct. 31, 2025 -- From October 28th to 30th, Kexing Biopharm participated in CPHI Frankfurt 2025, one of the world's most influential pharmaceutical exhibitions, presenting its key product portfolio and international commercialization solutions to partners from global markets. During the event, Kexing Biopharm's international business team held productive meetings with industry representatives from multiple countries. Discussions focused on topics such as product registration, market access, and localized collaboration strategies. The company also showcased its full-
- 김갑성 기자
- 2025-10-31 19:50
AXA BetterMe Weekend Celebrates Its 5th Anniversary with over 13,000 participants

[ 메디채널 노기식 기자 ] Spreading positivity across the city and inspiring everyone to achieve their BetterMe HONG KONG, Oct. 31, 2025 -- AXA Hong Kong and Macau ("AXA") successfully concluded its annual community carnival, the "AXA BetterMe Weekend", held from 25 to 26 October at AXA WONDERLAND, WestK. Celebrating its fifth anniversary this year, the event attracted over 13,000 participants. AXA brand ambassador Sammi Cheng graced the opening ceremony to officially kick start the event. She captivated the audience with her warm presence and engaging manner, infusing the
- 노기식 기자
- 2025-10-31 18:04
JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential

SHANGHAI, Oct. 31, 2025 -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the execution of an Amendment to its strategic collaboration agreement with Regeneron Pharmaceuticals, Inc. ("Regeneron"), a leading global biotechnology company. This amendment not only signifies a major upgrade in long-term partnership between the two companies, but also marks the beginning of a new phase of collaboration in TCR-T cell therapy and platform innovation. The
- 김갑성 기자
- 2025-10-31 17:38
Xinhua Silk Road: Chinese biz leaders hold talks to explore cultural inheritance, innovation

BEIJING, Oct. 31, 2025 -- On Tuesday, an in-depth talk between board chairmen of Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (Pien Tze Huang) and Kweichow Moutai Group highlighted joint effort to promote inheritance and innovation of traditional Chinese culture. After discussing related topics such as inheritance of time-honored Chinese brands, Lin Zhihui, board chairman of Pien Tze Huang and Chen Hua, chairman of Kweichow Moutai Group agreed to give full display to the two businesses' demonstration role in this regard. The two Chinese enterprises, whose brands are both fa
- 김갑성 기자
- 2025-10-31 16:15

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-11-02_SUN

2025-11-01_SAT

Manulife Hong Kong Supports 'Water Parade at Victoria Harbour' curated and organized by AllRightsReserved with Spectacular Drone Show Finale 23:49

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 02일 20시 20분